PHILADELPHIA--(BUSINESS WIRE)--Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Climb Bio ( (CLYM)) has issued an ...

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...

DSMB recommends continuing Phase 3 DRAGON trial for Tinlarebant in Stargardt disease without modifications; completion expected Q4 2025. Tinlarebant has received Fast Track, Rare Pediatric Disease, ...